Cargando…

FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease

Passive immunotherapy for Alzheimer disease has been tried for over 10 years without success. However, in 2021 and most recently in January 2023, the US Food and Drug Administration granted accelerated approval of 2 antibodies for this purpose, aducanumab and lecanemab. In both cases, the approval w...

Descripción completa

Detalles Bibliográficos
Autores principales: Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass, Barrio, Jorge R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317300/
https://www.ncbi.nlm.nih.gov/pubmed/37314733
http://dx.doi.org/10.1097/RLU.0000000000004710